Niacin (Nicotinic Acid)

Introduction Overview

Generic Name

niacin (nicotinic acid)

Brand Name

B-3-50, B3-500-Gr, Endur-acin, HDL Benefit, Niacin SR, Niacor, Niaspan ER, Slo-Niacin

Dosage Form

Oral tablets and extended-release formulations

Drug Class

Miscellaneous antihyperlipidemic agents, Vitamins (Vitamin B3)

Pharmacokinetics

Absorption:
Niacin is rapidly and extensively absorbed from the gastrointestinal tract following oral administration. It is well absorbed from the stomach and small intestine, with peak plasma concentrations typically occurring within 30 to 60 minutes for immediate-release formulations. The bioavailability of niacin from conventional oral dosage forms is approximately 60-80%. Extended-release formulations have altered absorption kinetics to prolong the release and minimize peak plasma levels to reduce adverse effects like flushing. Food intake may reduce the rate but not the extent of absorption. Absorption can be influenced by gastrointestinal pH and motility.

Distribution:
Once absorbed, niacin is widely distributed throughout body tissues, including the liver, adipose tissue, muscle, and kidney. It has a relatively low protein binding, approximately 30-35%, allowing free circulation in plasma. The volume of distribution is moderate and reflects distribution into total body water compartments. Niacin does not extensively cross the blood-brain barrier in significant amounts but can affect peripheral tissues. Distribution may vary in patients with altered plasma protein levels or in certain disease states.

Metabolism:
Niacin undergoes hepatic metabolism through two major pathways: conjugation with glycine to form nicotinuric acid and amidation to form nicotinamide, which is further metabolized to pyridones. The metabolic pathways are saturable at higher doses, particularly for immediate-release formulations, leading to nonlinear pharmacokinetics. The rate of metabolism influences the clinical effectiveness and toxicity profile of the drug. Extended-release formulations are designed to modulate metabolism to sustain blood levels while reducing peak-associated side effects. Metabolites are inactive and do not contribute to the lipid-altering effects.

Elimination:
Niacin and its metabolites are primarily eliminated via the kidneys through renal excretion. Approximately 50 to 75% of an oral dose is excreted in the urine within 24 hours. The elimination half-life varies between 20 to 45 minutes for immediate-release forms but can be extended with sustained-release formulations up to several hours due to altered absorption and metabolism. Renal clearance is an important factor, and patients with renal impairment may experience altered elimination patterns. There is no significant biliary or fecal excretion of unchanged drug.

Dosage Forms

Available Dosage Forms:
Niacin is available in several oral formulations, including:
- Immediate-release oral tablets: typically 50 mg, 100 mg, 250 mg, 500 mg, and 1000 mg strengths.
- Extended-release (ER) or sustained-release (SR) tablets/capsules: commonly 250 mg, 500 mg, and 750 mg.
- Controlled-release formulations branded as Niaspan with dosing strengths of 500 mg and 1000 mg.
- Combination products and vitamin supplements containing niacin in variable doses.

Dosages for Adults and Adolescents:
The therapeutic dosing of niacin for lipid disorders typically begins at low doses (e.g., 250 mg once daily) and is gradually titrated to minimize adverse effects such as flushing. Usual effective dosages range from 1 gram to 3 grams daily, divided into multiple doses for immediate-release forms, or once daily dosing for extended-release forms. Niaspan ER is often started at 500 mg at bedtime and titrated up to a maximum of 2000 mg daily. For vitamin supplementation, doses are typically much lower, consistent with recommended dietary allowances. Dose adjustments may be required based on lipid goals and patient tolerance.

Specific Patient Populations:
In patients with hepatic or renal impairment, dosage adjustments are necessary due to altered metabolism and elimination. Use in elderly patients may require cautious titration. Use during pregnancy is generally avoided due to insufficient safety data; breastfeeding is also contraindicated. Niacin dosing in children is not recommended without medical supervision given the risk of toxicity and variable pharmacokinetics. Dosage regimens should be individualized based on comorbid conditions such as diabetes, gout, or peptic ulcer disease to minimize risks.

Mechanism Of Action

Niacin (nicotinic acid) is a water-soluble B vitamin that exerts lipid-modifying effects by multiple mechanisms at the molecular and cellular level. Primarily, niacin inhibits hepatic synthesis of very-low-density lipoprotein (VLDL), which consequently reduces the production of low-density lipoprotein (LDL), known as 'bad cholesterol.' This mechanism significantly decreases plasma LDL cholesterol and triglyceride levels.

At the cellular level, niacin activates the GPR109A receptor (also known as HM74A), a G-protein-coupled receptor expressed on adipocytes. Activation of this receptor inhibits adenylate cyclase activity, decreasing cyclic AMP levels and suppressing hormone-sensitive lipase-mediated lipolysis. This results in reduced free fatty acid flux to the liver, decreasing substrate availability for triglyceride synthesis and thus lowering VLDL secretion.

Niacin also increases levels of high-density lipoprotein cholesterol (HDL-C), the 'good cholesterol,' by decreasing hepatic removal of apolipoprotein A-I, a major HDL structural component, thereby prolonging HDL half-life. This enhances reverse cholesterol transport, promoting cholesterol efflux from peripheral tissues to the liver for excretion.

Compared to other lipid-lowering agents such as statins, which inhibit HMG-CoA reductase to block cholesterol synthesis, niacin acts through unique pathways involving free fatty acid metabolism and HDL modulation. Clinical studies have demonstrated niacin's efficacy in improving lipid profiles and reducing cardiovascular event risk, although recent trials have questioned its additive benefit when used with statins. Nonetheless, its distinct mechanisms provide important therapeutic options, especially in patients with combined dyslipidemia.

Pharmacological Actions

Lowers low-density lipoprotein (LDL) cholesterol by inhibiting hepatic VLDL synthesis.
Reduces serum triglycerides through decreased free fatty acid mobilization from adipose tissue.
Increases high-density lipoprotein (HDL) cholesterol by reducing hepatic clearance of apolipoprotein A-I.
Improves overall lipid profile by modulating lipoprotein metabolism.
Acts as a vitamin (B3), contributing to normal cellular metabolism and enzymatic redox reactions.
Exerts vasodilatory effects via prostaglandin-mediated pathways causing flushing.
Possesses antioxidant properties that may reduce oxidative modification of lipoproteins.
Modulates inflammatory responses involved in atherosclerosis progression.
Potentially stabilizes atherosclerotic plaques through lipid profile improvement.
May improve endothelial function via lipid-independent mechanisms.

Therapeutic Or Clinical Uses

Treatment of dyslipidemia characterized by elevated LDL cholesterol and triglycerides.
Raising HDL cholesterol levels to reduce cardiovascular risk.
Reduction of the risk of myocardial infarction in patients with a history of heart attacks and high cholesterol.
Adjunct therapy to statins or other lipid-lowering drugs when lipid goals are not met.
Prevention of atherosclerotic plaque progression and cardiovascular events.
Management of pellagra, a niacin deficiency disease characterized by dermatitis, diarrhea, and dementia.
Used as a dietary supplement to prevent niacin deficiency.
Part of combination therapy in patients with hyperlipoproteinemia.
Supportive therapy in metabolic syndrome with mixed dyslipidemia.
Reduction of lipoprotein(a) levels in certain patients.

Side Or Adverse Effects

Flushing: sudden warmth, redness, itching, or tingling sensation under the skin.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, and indigestion.
Abnormal liver function tests reflecting possible hepatotoxicity, especially at high doses or with sustained-release formulations.
Itching and skin rash, dry skin or skin discoloration.
Headache and dizziness, particularly on rising from sitting or lying position.
Elevated blood glucose levels potentially exacerbating diabetes control.
Hyperuricemia leading to gout or worsening of preexisting gout.
Rare allergic reactions including rash, urticaria, or anaphylaxis.
Cough and respiratory symptoms.
Jaundice or signs of liver injury with prolonged or high-dose use.
Light-headedness or syncope due to orthostatic hypotension.
Muscle pain or weakness rarely observed, necessitating evaluation.
Increased risk of bleeding when combined with anticoagulants.
Visual disturbances and blurred vision in rare cases.
Potential worsening of peptic ulcers.

Precautions

Use cautiously in patients with preexisting liver disease or elevated hepatic enzymes.
Monitor blood glucose closely in diabetic patients; dose adjustments may be required.
Avoid in patients with active peptic ulcer or significant gastrointestinal bleeding.
Careful monitoring is advised for patients with gout or hyperuricemia.
May cause orthostatic hypotension; patients should rise slowly from sitting or lying positions.
Not recommended for use during pregnancy unless clearly needed; consult healthcare provider.
Avoid concurrent use with hepatotoxic drugs to minimize risk of liver injury.
Use with caution in elderly patients with cardiovascular or renal impairment.
Flushing reaction may be aggravated by alcohol or hot beverages; avoidance recommended.
Do not use extended-release forms interchangeably with immediate-release formulations without medical supervision.
Patients should adhere to prescribed dosing schedules and not abruptly discontinue therapy without consultation.
Advise patients about potential effect on certain laboratory tests.
Use caution if patient is receiving anticoagulants due to bleeding risk.
Consider baseline and follow-up liver function tests during therapy.
Avoid use in breastfeeding women due to potential neonatal risk.

Warnings

Contraindicated in severe liver disease given potential hepatotoxicity.
Avoid in patients with active peptic ulcer or gastrointestinal bleeding.
Risk of serious flushing reactions which may increase fall risk due to dizziness.
Use cautiously in patients with unstable angina or acute myocardial infarction.
Avoid concomitant use with bile acid sequestrants; if necessary, stagger dosing by 4 to 6 hours.
Monitor for signs of hepatotoxicity including jaundice, dark urine, or abdominal pain.
May raise serum glucose levels; monitor diabetic patients regularly.
Risk of hyperuricemia and gout exacerbation with high doses.
Use caution with other lipid-lowering agents to avoid additive adverse effects.
Potential interactions with anticoagulants may enhance bleeding risk.
Not recommended for use in children without medical supervision.
May potentiate orthostatic hypotension especially with antihypertensive agents.
Avoid alcohol consumption during therapy to reduce risk of liver injury and flushing.
Discontinue if signs of allergic reaction such as hives or respiratory distress occur.
Flushing and pruritus often diminish over time but may necessitate medication adjustments.

Contraindication

Known hypersensitivity to niacin or nicotinic acid derivatives.
Severe hepatic impairment or active liver disease.
Active peptic ulcer disease with ongoing bleeding.
Arterial bleeding or active hemorrhagic conditions.
Patients with unexplained muscle pain or elevated creatine kinase should avoid use.
Concomitant use of other hepatotoxic drugs without close monitoring.
Pregnancy when benefits do not outweigh risks; safest to avoid.
Breastfeeding due to potential adverse effects on the infant.
Severe hypotension or history of orthostatic syncope.
Unstable angina or recent myocardial infarction until stabilized.
Severe renal impairment without careful dose adjustment.
Children without specific medical recommendation.
Concomitant use with colestipol or cholestyramine without proper dosing intervals.
History of hypersensitivity reactions to extended-release niacin products.
Use with caution if underlying dermatologic disorders are present.

Drug Interactions

Bile acid sequestrants (colestipol, cholestyramine) reduce absorption; stagger dosing by 4 to 6 hours.
Antiplatelet agents and anticoagulants (warfarin, Coumadin, Jantoven) may increase bleeding risk.
Other lipid-lowering agents may increase risk of adverse effects; monitor closely.
Alcohol potentiates flushing and increases risk of hepatotoxicity.
Aspirin or NSAIDs can reduce niacin-induced flushing and may be used prophylactically.
Blood pressure medications may have additive hypotensive effects with niacin.
Drugs affecting liver metabolism may alter niacin levels and toxicity profile.
Diabetes medications may need adjustment due to niacin-induced hyperglycemia.
Drugs that increase uric acid levels (e.g., diuretics) may exacerbate gout risk.
Concomitant use with hepatotoxic drugs increases liver injury risk.
Interactions with certain vitamins or supplements may alter niacin efficacy.
Concomitant use with alcohol-containing products should be avoided.
Potential interference with laboratory assays including liver function tests.
Caution with CYP450 enzyme modulators as they may impact drug metabolism.
Close monitoring when used with other medications affecting lipid metabolism.

Preparations Of The Drug

Immediate-release oral tablets in strengths 50 mg, 100 mg, 250 mg, 500 mg, and 1000 mg.
Extended-release (sustained-release) formulations to minimize flushing, available in 250 mg, 500 mg, and 750 mg tablets or capsules.
Niaspan branded extended-release tablets designed for once-daily dosing.
Combination multivitamin preparations containing niacin as vitamin B3 in varying lower doses.
Beaded or microencapsulated formulations aimed at reducing gastrointestinal irritation.
Over-the-counter vitamin B-complex supplements including niacin.
Topical niacin preparations for dermatological indications (not for lipid control).
Provision in injectable formulations primarily for research or deficiency states (rare use).
Various generic and branded versions with specific release characteristics.
Prescription-only formulations requiring physician supervision due to potency and risks.
Enteric-coated tablets to reduce gastric irritation in specific products.
Novel extended-release formulations with modified pharmacokinetic profiles under development.
Combination products containing niacin with other lipid-lowering agents available in some markets.
Niacinamide (nicotinamide) forms not effective for lipid control but used as vitamin supplement.